Zealand seeks deals in obesity and beyond
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
Boehringer signals intent in obesity
Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
